

# Medicine And Pharmacological Management Of Diabetes Mellitus: A Review

<sup>1</sup>Amol Ramesh Thombre, <sup>2</sup>Mayuri B. Mokal, <sup>3</sup>Dr. D.K. Vir, <sup>4</sup>Saurabh Sanjay Wagh, <sup>5</sup>Deepak Sainath More.

1) <sup>1</sup>Student, 2) <sup>2</sup>Associate professor, 3) <sup>3</sup>Principal, 4) <sup>4</sup>Student, 5) <sup>5</sup>Student

Department of Pharmaceutical Science and Technology.

Shree Goraksha College of Pharmacy & Research Centre, Chhatrapati Sambhaji Nagar, India

**Abstract** - Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. It represents a major global health concern, contributing significantly to morbidity, mortality, and economic burden worldwide. Effective management of DM requires a multifaceted approach combining lifestyle modifications, patient education, and pharmacological therapy to achieve optimal glycaemic control and reduce complications. Conventional pharmacological management includes insulin and various classes of oral hypoglycaemic agents such as biguanides, sulfonylureas, thiazolidinedione's, and alpha-glucosidase inhibitors. Recent advancements have introduced novel therapeutic approaches, including incretin-based therapies and sodium-glucose co-transporter 2 (SGLT2) inhibitors, which provide improved glycaemic control with added cardiovascular and renal benefits. Furthermore, emerging technologies such as nanomedicines and personalized medicine are revolutionizing diabetes management by enabling targeted drug delivery, enhanced bioavailability, and individualized treatment strategies. This review provides a comprehensive overview of current pharmacological agents and recent innovations in diabetes therapy, emphasizing the importance of integrating traditional and modern approaches for improved patient outcomes.

**Keywords:** Diabetes mellitus, hyperglycemia, pharmacological management, insulin therapy, SGLT2 inhibitors, personalized medicine

## 1. Introduction

Diabetes mellitus (DM) is one of the most widespread and rapidly growing non-communicable diseases globally, posing a serious threat to public health and healthcare systems. According to the International Diabetes Federation (IDF), over 500 million adults were living with diabetes as of 2023, and this number is projected to rise dramatically in the coming decades due to sedentary lifestyles, obesity, and unhealthy dietary habits (1). The disease is characterized by chronic hyperglycemia caused by impaired insulin secretion, defective insulin action, or a combination of both (2). Insulin, a hormone produced by the pancreatic  $\beta$ -cells, plays a crucial role in maintaining glucose homeostasis by promoting glucose uptake into tissues and inhibiting hepatic glucose production. When insulin regulation is disrupted, glucose accumulates in the bloodstream, leading to long-term metabolic imbalances and organ damage.

Diabetes mellitus is primarily classified into three major types: Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM) (3). Type 1 diabetes is an autoimmune disorder characterized by the destruction of pancreatic  $\beta$ -cells, resulting in absolute insulin deficiency. In contrast, Type 2 diabetes, the most common form, arises from insulin resistance combined with a relative lack of insulin secretion. Gestational diabetes occurs during pregnancy due to hormonal changes that cause temporary insulin resistance. Apart from these, other less common forms include monogenic diabetes and secondary diabetes caused by medications or other diseases.

The global increase in diabetes prevalence has been accompanied by a parallel rise in diabetes-related complications, which significantly impact quality of life and life expectancy. Chronic hyperglycemia damages blood vessels and nerves, leading to severe complications such as cardiovascular diseases, nephropathy, neuropathy, and retinopathy (4). Moreover, diabetes is one of the leading causes of blindness, kidney failure, and lower limb amputations worldwide. The socioeconomic burden of the disease is immense, encompassing both direct medical costs and indirect losses related to reduced productivity and premature mortality.




**Figure 1 : The Critical Role of Pharmacist Counselling in Diabetes Care in the Indian.**

The management of diabetes mellitus is complex and multifactorial, requiring a combination of lifestyle modification, patient education, dietary regulation, and pharmacological therapy. The primary goal of treatment is to maintain blood glucose levels within the normal physiological range while minimizing the risk of hypoglycemia and preventing both microvascular and macrovascular complications (5). Pharmacological therapy plays a pivotal role in diabetes management, with several classes of drugs available to target different mechanisms involved in glucose metabolism. Traditional therapies such as insulin and oral hypoglycaemic agents—biguanides, sulfonylureas, thiazolidinedione's, and alpha-glucosidase inhibitors—have been the cornerstone of diabetes treatment for decades. However, recent advances in pharmacology have led to the development of novel therapeutic agents like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose co-transporter-2 (SGLT2) inhibitors, offering improved glycaemic control and added cardiovascular benefits.

Furthermore, emerging approaches such as nanotechnology, gene therapy, and personalized medicine are transforming diabetes management by enabling targeted drug delivery, enhanced bioavailability, and individualized treatment strategies based on genetic and metabolic profiles. These advancements mark a significant step toward precision medicine, improving outcomes and reducing complications. Despite the progress, challenges remain in ensuring equitable access to advanced therapies, promoting patient adherence, and addressing lifestyle-related risk factors through public health initiatives.

## 2. Pathophysiology of Diabetes Mellitus

Diabetes mellitus (DM) is a complex metabolic disorder primarily characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The disease pathophysiology varies among its different types but ultimately leads to disturbances in carbohydrate, fat, and protein metabolism. Persistent elevation of blood glucose levels initiates a cascade of biochemical and molecular alterations that contribute to both acute metabolic crises and chronic complications affecting multiple organ systems.



**Figure 2 : Pathophysiology of Diabetes Mellitus**

### 2.1 Type 1 Diabetes Mellitus (T1DM)

Type 1 diabetes mellitus is an autoimmune disorder resulting from the selective destruction of insulin-producing  $\beta$ -cells in the pancreatic islets of Langerhans. This process is mediated by autoreactive T-lymphocytes and is often associated with the presence of autoantibodies such as islet cell antibodies (ICA), insulin autoantibodies (IAA), and glutamic acid decarboxylase antibodies GADA. The destruction of  $\beta$ -cells leads to an absolute deficiency of insulin, a hormone essential for glucose uptake and utilization in peripheral tissues. In the absence of insulin, glucose cannot enter muscle and adipose tissues effectively, leading to hyperglycemia, lipolysis, and ketogenesis. Over time, patients develop symptoms such as polyuria, polydipsia, polyphagia, weight loss, and fatigue. If untreated, this can progress to life-threatening diabetic ketoacidosis (DKA), a hallmark of insulin deficiency.

### 2.2 Type 2 Diabetes Mellitus (T2DM)

Type 2 diabetes mellitus, the most prevalent form of diabetes, is characterized by insulin resistance in peripheral tissues (such as skeletal muscle, liver, and adipose tissue) and an inadequate compensatory insulin secretory response from pancreatic  $\beta$ -cells. Initially, the pancreas responds to insulin resistance by increasing insulin production, but over time,  $\beta$ -cell dysfunction ensues due to chronic hyperglycemia, lipotoxicity, and glucotoxicity. Insulin resistance in skeletal muscle reduces glucose uptake, while in the liver it fails to suppress hepatic gluconeogenesis, leading to increased endogenous glucose production.

Adipose tissue dysfunction further exacerbates metabolic imbalance by releasing excess free fatty acids and inflammatory cytokines such as TNF- $\alpha$  and IL-6, which impair insulin signaling pathways. Thus, Type 2 diabetes represents a dual defect involving both insulin resistance and  $\beta$ -cell dysfunction, often associated with obesity, sedentary lifestyle, and genetic predisposition.

### **2.3 Molecular Mechanisms Underlying Hyperglycemia and Complications**


Chronic hyperglycemia exerts harmful effects through several interrelated mechanisms, including oxidative stress, advanced glycation end-product (AGE) formation, activation of protein kinase C (PKC), and increased flux through the polyol pathway (8). Excess glucose enhances mitochondrial reactive oxygen species (ROS) production, leading to oxidative damage of cellular proteins, lipids, and DNA. The accumulation of AGEs causes cross-linking of proteins and triggers inflammatory signaling cascades that damage endothelial cells and impair vascular function. Additionally, activation of the PKC pathway promotes vasoconstriction, inflammation, and basement membrane thickening, all of which contribute to microvascular complications such as retinopathy, nephropathy, and neuropathy. Endothelial dysfunction, resulting from oxidative and inflammatory stress, plays a crucial role in the development of macrovascular complications including atherosclerosis, coronary artery disease, and peripheral vascular disease.

### **2.4 Therapeutic Implications in Pathophysiology**

Understanding the pathophysiological mechanisms of diabetes provides a foundation for targeted pharmacological interventions. The primary goals of therapy are to restore normal glucose homeostasis by improving insulin sensitivity, enhancing insulin secretion, suppressing hepatic glucose output, and increasing peripheral glucose uptake (9). In Type 1 diabetes, exogenous insulin replacement is essential to compensate for absolute insulin deficiency. In contrast, pharmacological management of Type 2 diabetes employs agents such as biguanides (metformin) to suppress hepatic gluconeogenesis, thiazolidinedione's to improve insulin sensitivity, sulfonylureas and meglitinides to stimulate insulin secretion, and incretin-based drugs (GLP-1 receptor agonists and DPP-4 inhibitors) to enhance glucose-dependent insulin release. Newer agents like SGLT2 inhibitors reduce blood glucose levels by promoting urinary glucose excretion and offer cardiovascular and renal protection.

## **3. Pharmacological Management of Diabetes**

The pharmacological management of diabetes mellitus aims to achieve and maintain normoglycemia while preventing both short- and long-term complications. Since diabetes is a progressive metabolic disorder, pharmacotherapy must often evolve over time, transitioning from monotherapy to combination therapy as  $\beta$ -cell function declines. The therapeutic strategy is individualized, considering factors such as age, weight, comorbidities, risk of hypoglycemia, and treatment adherence. The major pharmacological options include insulin therapy, oral hypoglycaemic agents, incretin-based therapies, and sodium-glucose co-transporter-2 (SGLT2) inhibitors.



**Figure 3 : Mechanism of Action of Major Antidiabetic Drugs**

### 3.1 Insulin Therapy

Insulin remains the cornerstone of therapy for patients with Type 1 diabetes mellitus (T1DM) and those with advanced Type 2 diabetes mellitus (T2DM) where oral medications fail to maintain adequate glycaemic control. Various insulin formulations are available, classified based on their onset and duration of action—rapid-acting (insulin lispro, aspart), short-acting (regular insulin), intermediate-acting (NPH), and long-acting (glargine, detemir)

The advent of insulin analogues has significantly improved glycaemic control by providing more predictable absorption patterns, reducing the risk of hypoglycaemia, and mimicking physiological insulin secretion more closely. Advanced delivery technologies such as insulin pumps and continuous glucose monitoring (CGM) devices have revolutionized diabetes management, offering improved dosing accuracy, flexibility, and patient convenience. Together, these innovations enhance metabolic outcomes and reduce the burden of daily injections and glucose fluctuations.

### 3.2 Oral Hypoglycaemic Agents

Oral hypoglycaemic agents are primarily used in Type 2 diabetes mellitus (T2DM), where insulin resistance and  $\beta$ -cell dysfunction coexist. These agents act through various mechanisms to lower blood glucose levels effectively.

#### a. Biguanides

Metformin is the first-line therapy for T2DM due to its proven efficacy, safety profile, and cardiovascular benefits (14). It lowers blood glucose by reducing hepatic gluconeogenesis and improving peripheral insulin sensitivity, without causing significant hypoglycaemia.

#### b. Sulfonylureas

Sulfonylureas stimulate insulin secretion from pancreatic  $\beta$ -cells by blocking ATP-sensitive potassium ( $K^+$ ) channels (16). Common examples include glimepiride, glibenclamide, and gliclazide (17). While

effective, their use is often limited by the risk of hypoglycemia and weight gain, particularly in elderly or renally impaired patients.

### c. Meglitinides

Drugs such as repaglinide and nateglinide act similarly to sulfonylureas but have a shorter duration of action, offering better control of postprandial hyperglycemia with a reduced risk of hypoglycemia. They are often preferred in patients with irregular meal patterns.

### d. Thiazolidinedione's (TZDs)

Thiazolidinedione's, including pioglitazone and rosiglitazone, enhance insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR- $\gamma$ ) in adipose tissue and skeletal muscle. They improve glucose uptake and reduce hepatic glucose production but may cause weight gain, fluid retention, and an increased risk of heart failure in susceptible individuals.

### e. Alpha-Glycosidase Inhibitors

Agents such as acarbose and miglitol work by inhibiting intestinal  $\alpha$ -glucosidase enzymes, delaying carbohydrate digestion and glucose absorption. They are particularly effective in controlling postprandial hyperglycemia and are often used as adjunctive therapy. Gastrointestinal discomfort is the most common side effect associated with their use.

## 3.3 Incretin-Based Therapies

Incretin-based therapies target the incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)—which regulate glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release in a glucose-dependent manner.

- a. **GLP-1 Receptor Agonists (GLP-1 RAs)** such as exenatide and liraglutide enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, leading to improved glycaemic control and modest weight loss.
- b. **Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)** including sitagliptin, vildagliptin, and saxagliptin act by inhibiting the enzyme DPP-4, which degrades incretin hormones, thereby prolonging their activity. These agents offer effective glucose control with a low risk of hypoglycemia and are well tolerated in combination therapy.

## 3.4 SGLT2 Inhibitors

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, including dapagliflozin, empagliflozin, and canagliflozin, act by inhibiting glucose reabsorption in the renal proximal tubules, leading to increased urinary glucose excretion and reduced blood glucose levels. Besides lowering plasma glucose, they promote weight loss, reduce blood pressure, and have shown cardiovascular and renal protective effects in large clinical trials (24). Common side effects include genital mycotic infections and dehydration due to osmotic diuresis.

## 3.5 Combination Therapy

Given the progressive nature of diabetes, combination therapy is often required to achieve sustained glycaemic control. Combining agents with complementary mechanisms of action enhances efficacy while minimizing the adverse effects associated with high doses of monotherapy. Common combinations include metformin with sulfonylureas, DPP-4 inhibitors, or SGLT2 inhibitors, providing synergistic effects on insulin sensitivity, secretion, and glucose elimination. Fixed-dose combinations improve patient adherence and simplify treatment regimens.

## 4 Emerging Therapies

The landscape of diabetes management is rapidly evolving, driven by advancements in molecular biology, biotechnology, and pharmaceutical innovation. While conventional therapies focus on controlling blood glucose levels and preventing complications, emerging treatments aim to address the root causes of diabetes—such as  $\beta$ -cell dysfunction, insulin resistance, and autoimmune destruction—and to provide more durable, physiological glycaemic control. These novel approaches hold promise for improving patient outcomes, reducing treatment burden, and potentially achieving long-term remission or cure.

### 4.1 Dual GIP/GLP-1 Receptor Agonists

One of the most promising recent developments is the introduction of dual glucose-dependent insulintropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, exemplified by tirzepatide. This novel class of drugs combines the actions of both incretin hormones to enhance insulin secretion, suppress glucagon release, and improve insulin sensitivity. Clinical trials have demonstrated that tirzepatide produces superior glycaemic control and significant weight reduction compared to existing GLP-1 receptor agonists. Additionally, its favorable effects on lipid metabolism and cardiovascular risk markers suggest potential benefits beyond glucose regulation. The dual agonist mechanism offers a comprehensive approach to addressing multiple metabolic dysfunctions associated with Type 2 diabetes mellitus (T2DM).

### 4.2 Nanotechnology-Based Drug Delivery Systems

Nanotechnology has emerged as a revolutionary platform in diabetes pharmacology, offering targeted, sustained, and efficient drug delivery. Nanocarrier systems, including liposomes, polymeric nanoparticles, and nanoemulsions, are being developed to improve the bioavailability and stability of insulin and other antidiabetic drugs. Nanoparticle-mediated insulin delivery can protect insulin from enzymatic degradation and allow for controlled release, reducing the frequency of injections and minimizing glycaemic fluctuations. Furthermore, oral and transdermal nanoformulations are being explored to overcome the limitations of subcutaneous insulin administration. Nanotechnology also enables glucose-responsive systems that can automatically modulate insulin release based on real-time glucose levels, functioning as a form of “smart insulin therapy.” These advancements have the potential to transform diabetes care by improving patient compliance and treatment precision.

### 4.3 Gene Therapy

Gene therapy represents a ground-breaking avenue for potentially curative treatment of diabetes. It involves the introduction of functional genes to restore or enhance insulin production, regulate glucose metabolism, or suppress autoimmune responses. For Type 1 diabetes mellitus (T1DM), gene therapy approaches focus on transferring insulin-producing genes to non- $\beta$  cells, such as hepatocytes, to re-establish endogenous insulin production. In Type 2 diabetes, gene-based interventions target insulin resistance pathways or  $\beta$ -cell regeneration. Viral vectors such as adeno-associated viruses (AAV) and lentiviruses are being utilized to deliver therapeutic genes safely and effectively. Although still in experimental stages, gene therapy holds the promise of achieving long-term glycaemic stability with minimal external intervention.

### 4.4 Stem Cell Therapy and $\beta$ -Cell Regeneration

Stem cell therapy has emerged as a promising frontier in diabetes research, particularly for restoring pancreatic  $\beta$ -cell function (29). Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), can be differentiated into insulin-producing  $\beta$ -like cells capable of responding to glucose fluctuations. Transplantation of these regenerated cells into diabetic patients could

potentially re-establish natural insulin secretion. Ongoing studies are also exploring encapsulation technologies that protect transplanted cells from immune destruction while allowing insulin diffusion. Early clinical trials have shown encouraging results, indicating partial restoration of insulin independence in Type 1 diabetic patients. Stem cell-based strategies may ultimately pave the way for biological cures for diabetes by regenerating or replacing dysfunctional pancreatic tissue.

#### **4.5 Future Directions**

The integration of these emerging therapies with precision medicine, artificial intelligence, and continuous glucose monitoring technologies is expected to reshape diabetes management. Personalized treatment algorithms based on genetic, metabolic, and behavioural profiles could optimize therapy selection and enhance long-term outcomes. Furthermore, combining pharmacological innovation with lifestyle interventions and digital health platforms may enable more effective, patient-centred diabetes care...

### **5 Personalized Medicine in Diabetes**

Personalized medicine represents a transformative approach in diabetes management, emphasizing individualized treatment based on a patient's genetic makeup, metabolic profile, and lifestyle factors. Unlike conventional "one-size-fits-all" therapy, this approach recognizes the genetic and physiological diversity among diabetic patients, which influences drug response, efficacy, and the risk of adverse effects. Through the integration of pharmacogenomics, molecular diagnostics, and precision-based healthcare, personalized medicine aims to optimize glycaemic control and improve overall treatment outcomes.

#### **5.1 Role of Pharmacogenomics in Diabetes Management**

Pharmacogenomics, the study of how genetic variations affect drug metabolism and therapeutic response, has significantly advanced the understanding of inter-individual variability in diabetes treatment. Genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors can alter the pharmacokinetics and pharmacodynamics of antidiabetic agents. For example, variations in the CYP2C9 gene influence the metabolism of sulfonylureas, potentially affecting drug efficacy and the risk of hypoglycaemia. Similarly, OCT1 gene polymorphisms can modify the hepatic uptake and action of metformin, leading to differences in glycaemic response among individuals. Understanding these genetic factors allows clinicians to select and dose medications more accurately, enhancing therapeutic effectiveness and minimizing adverse events.

#### **5.2 Individualized Therapy Based on Genetic and Clinical Factors**

Personalized medicine in diabetes extends beyond pharmacogenomics to include a patient's clinical characteristics, lifestyle habits, and environmental influences. Factors such as age, body mass index (BMI), ethnicity, comorbidities, diet, and physical activity play critical roles in determining drug response. For instance, obese patients with insulin resistance may benefit more from insulin sensitizers like thiazolidinedione's, whereas lean patients with insulin secretory defects may respond better to insulin secretagogues. Genetic testing combined with clinical profiling helps tailor drug selection to individual needs, thereby improving treatment adherence and outcomes.

### 5.3 Biomarker-Based Treatment Optimization

The identification of biomarkers—such as genetic variants, circulating microRNAs, and metabolomics signatures—has enabled more precise disease stratification and drug response prediction. These biomarkers can be used to monitor disease progression, predict therapeutic success, and adjust treatment regimens accordingly. For example, biomarkers linked to  $\beta$ -cell function or insulin resistance can guide the choice between insulin therapy, incretin-based drugs, or SGLT2 inhibitors. Continuous glucose monitoring (CGM) and digital health tools further enhance personalization by providing real-time feedback on treatment effectiveness and lifestyle impact.

### 5.4 Integration of Digital Health and Artificial Intelligence (AI)

The incorporation of digital technologies, such as AI-driven analytics, mobile health applications, and wearable sensors, has accelerated the implementation of personalized medicine in diabetes care. Artificial intelligence algorithms can analyze large datasets—including glucose trends, dietary patterns, and genetic information—to generate individualized treatment recommendations. These tools support clinicians in making data-driven decisions while empowering patients to actively participate in managing their condition. Personalized digital platforms can also predict hypoglycaemic events, optimize insulin dosing, and improve medication adherence...

## 6 Advantages and Disadvantages of Personalized Medicine in Diabetes

### 6.1 Advantages

#### 1. Optimized Drug Therapy

- Personalized medicine allows for the selection of drugs based on genetic makeup, ensuring maximum efficacy and minimizing therapeutic failure.

#### 2. Reduced Adverse Drug Reactions

- Genetic testing identifies patients at risk of drug intolerance or hypersensitivity, thereby reducing unwanted side effects and complications.

#### 3. Improved Glycemic Control

- Tailoring medications and doses based on individual metabolic responses helps achieve better blood glucose regulation and reduces fluctuations.

#### 4. Enhanced Patient Adherence

- Patients receiving individualized treatment plans often experience fewer side effects and improved satisfaction, leading to higher treatment adherence.

#### 5. Early Disease Detection and Prevention

- Genetic and biomarker screening enables **early** identification of individuals at high risk, allowing preventive strategies before diabetes fully develops.

#### 6. Cost-Effectiveness in the Long Term

- Although initial testing is expensive, personalized treatment reduces hospitalization, complications, and trial-and-error prescriptions, leading to lower overall costs.

## 7. Integration of Digital Health Tools

- AI-driven systems and wearable devices provide real-time glucose monitoring, enabling dynamic and precise therapeutic adjustments.

## 8. Minimization of Treatment Resistance

- Pharmacogenomic profiling helps prevent ineffective therapy cycles and delays in treatment adjustments by predicting non-responsiveness early.

## 9. Better Management of Comorbidities

- Personalized therapy considers coexisting conditions like hypertension or obesity, ensuring safe and comprehensive disease management.

## 10. Advancement in Research and Innovation

- Continuous data collection from personalized treatment supports genomic and pharmacological research, leading to the discovery of new therapeutic targets.

### 6.2 Disadvantages

#### 1. High Initial Cost

- Genetic testing, data analysis, and AI-based monitoring systems are expensive, limiting accessibility for patients in low-resource settings.

#### 2. Limited Availability of Genetic Testing

- Many healthcare centers lack the infrastructure or trained professionals for pharmacogenomics testing and data interpretation.

#### 3. Ethical and Privacy Concerns

- The use of genetic data raises issues related to patient privacy, data ownership, and potential misuse by insurers or employers.

#### 4. Complexity of Genetic Variability

- Diabetes is influenced by multiple genes and environmental factors, making it challenging to establish precise genotype–phenotype correlations.

#### 5. Inequality in Healthcare Access

- Personalized medicine may widen the gap between high-income and low-income populations due to disparities in technology access and affordability.

## 7 Conclusion

The pharmacological management of diabetes mellitus has undergone significant evolution, integrating traditional therapies with novel agents and cutting-edge technologies. While insulin and metformin continue to form the foundation of treatment, newer drug classes such as incretin-based therapies and SGLT2 inhibitors have expanded therapeutic possibilities, offering improved glycaemic control, cardiovascular benefits, and enhanced patient quality of life. Advances in nanotechnology, gene therapy,

and personalized medicine promise more precise, targeted, and potentially curative approaches, enabling treatment to be tailored to individual genetic, metabolic, and lifestyle profiles. Despite these innovations, the cornerstone of effective diabetes management remains a multifaceted approach, combining pharmacotherapy with lifestyle modifications, patient education, and continuous monitoring to prevent complications and achieve long-term glycaemic stability. Future research should continue to focus on precision medicine and regenerative strategies, aiming to optimize therapeutic outcomes, minimize adverse effects, and ultimately reduce the global burden of diabetes. The integration of traditional and emerging therapies underscores the potential for a more personalized, effective, and sustainable diabetes care paradigm.

## 8 References

- 1) Pareek H, Sharma S, Khajja BS, Jain K, Jain GC. Evaluation of hypoglycaemic and anti hyperglycemic potential of *Tridax procumbens* (Linn.) BMC Complement Altern Med. 2009;9:48. doi: 10.1186/1472-6882-9-48.
- 2) Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. *Pediatr Diabetes*. 2009;10:3–12. doi: 10.1111/j.1399-5448.2009.00568.x.
- 3) Thévenod F. Pathophysiology of diabetes mellitus type 2: Roles of obesity, insulin resistance and  $\beta$ -cell dysfunction. *Front Diabetes Basel Karger*. 2008;19:1–18.
- 4) Patel DK, Kumar R, Prasad SK, Sairam K, Hemalatha S. Antidiabetic and in vitro antioxidant potential of *Hybanthus enneaspermus* (Linn) F. Muell in streptozotocin-induced diabetic rats. *Asian Pac J Trop Biomed*. 2011;1:316–322. doi: 10.1016/S2221-1691(11)60051-8.
- 5) Patel DK, Kumar R, Prasad SK, Hemalatha S. *Pedalium murex* Linn (Pedaliaceae) fruits: A comparative antioxidant activity of its different fractions. *Asian Pac J Trop Biomed*. 2011;1:395–400. doi: 10.1016/S2221-1691(11)60087-7.
- 6) Jung HA, Islam MD, Kwon YS, Jin SE, Son YK, Park JJ, et al. Extraction and identification of three major aldose reductase inhibitors from *Artemisia montana*. *Food Chem Toxicol*. 2011;49:376–384. doi: 10.1016/j.fct.2010.11.012.
- 7) Warjeet Singh L. Traditional medicinal plants of Manipur as anti-diabetics. *J Med Plants Res*. 2011;5:677–687.
- 8) Meenakshi P, Bhuvaneshwari R, Rathi MA, Thirumoorthi L, Guravaiah DC, Jiji MJ, et al. Antidiabetic activity of ethanolic extract of *Zaleya decandra* in alloxan-induced diabetic rats. *Appl Biochem Biotechnol*. 2010;162:1153–1159. doi: 10.1007/s12010-009-8871-x.
- 9) Balaraman AK, Singh J, Dash S, Maity TK. Antihyperglycemic and hypolipidemic effects of *Melothria maderaspatana* and *Coccinia indica* in Streptozotocin induced diabetes in rats. *Saudi Pharm J*. 2010;18:173–178. doi: 10.1016/j.jsps.2010.05.009.
- 10) Fröde TS, Medeiros YS. Animal models to test drugs with potential antidiabetic activity. *J Ethnopharmacol*. 2008;115:173–183. doi: 10.1016/j.jep.2007.10.038.
- 11) Dewanjee S, Das AK, Sahu R, Gangopadhyay M. Antidiabetic activity of *Diospyros peregrina* fruit: effect on hyperglycemia, hyperlipidemia and augmented oxidative stress in experimental type 2 diabetes. *Food Chem Toxicol*. 2009;47:2679–2685. doi: 10.1016/j.fct.2009.07.038.
- 12) Bagri P, Ali M, Aeri V, Bhowmik M, Sultana S. Antidiabetic effect of *Punica granatum* flowers: Effect on hyperlipidemia, pancreatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. *Food Chem Toxicol*. 2009;47:50–54. doi: 10.1016/j.fct.2008.09.058.
- 13) Ding Z, Lu Y, Lu Z, Lv F, Wang Y, Bie Y, et al. Hypoglycaemic effect of comatin, an antidiabetic substance separated from *Coprinus comatus* broth, on alloxan-induced-diabetic rats. *Food Chem*. 2010;121:39–43.
- 14) Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview. *Indian J Med Res*. 2007;125:451–472.

- 15) Venkatesh S, Madhava Reddy B, Dayanand Reddy G, Mullangi R, Lakshman M. Antihyperglycemic and hypolipidemic effects of *Helicteres isora* roots in alloxan-induced diabetic rats: A possible mechanism of action. *J Nat Med*. 2010;64:295–304. doi: 10.1007/s11418-010-0406-9.
- 16) Modak M, Dixit P, Londhe J, Ghaskadbi S, Paul A, Devasagayam T. Indian herbs and herbal drugs used for the treatment of diabetes. *J Clin Biochem Nutr*. 2007;40:163–173. doi: 10.3164/jcbrn.40.163.
- 17) Feshani AM, Kouhsari SM, Mohammadi S. *Vaccinium arctostaphylos*, a common herbal medicine in Iran: molecular and biochemical study of its antidiabetic effects on alloxan-diabetic Wistar rats. *J Ethnopharmacol*. 2011;133:67–74. doi: 10.1016/j.jep.2010.09.002.
- 18) Patel DK, Kumar R, Laloo D, Hemalatha S. Evaluation of phytochemical and antioxidant activities of the different fractions of *Hybanthus enneaspermus* (Linn.) F. Muell. (Violaceae) *Asian Pac J Trop Med*. 2011;4:391–396. doi: 10.1016/S1995-7645(11)60110-7.
- 19) Bnouham M, Ziyyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential antidiabetic activity - A review of ten years of herbal medicine research (1990–2000) *Int J Diabetes Metab*. 2006;14:1–25.
- 20) Patil RN, Patil RY, Ahirwar A, Ahirwar D. Evaluation of antidiabetic and related actions of some Indian medicinal plants in diabetic rats. *Asian Pac J Trop Med*. 2011;4:20–23. doi: 10.1016/S1995-7645(11)60025-4.
- 21) Geetha G, Kalavalarasariel Gopinathapillai P, Sankar V. Anti diabetic effect of *Achyranthes rubrofusca* leaf extracts on alloxan induced diabetic rats. *Pak J Pharm Sci*. 2011;24:193–199.
- 22) Ravikumar R, Krishnamoorthy P, Kalidoss A. Antidiabetic and antioxidant efficacy of *Andrographis paniculata* in alloxanized albino rats. *Int J Pharm Technol*. 2010;2:1016–1027.